What is Translate Bio's (TBIO) profit margin?
Translate Bio had a net margin of 17.97% and a trailing twelve-month return on equity of 1.50%. View Translate Bio's earnings history. What price target have analysts set for TBIO? 8 brokerages have issued 1 year target prices for Translate Bio's stock. Their forecasts range from $20.00 to $38.00.
Is Translate Bio (TBIO) a buy or sell?
According to the issued ratings of 8 analysts in the last year, the consensus rating for Translate Bio stock is Hold based on the current 7 hold ratings and 1 buy rating for TBIO. The average twelve-month price target for Translate Bio is $27.50 with a high price target of $38.00 and a low price target of $20.00. Learn more
What is the price target for Translate Bio stock?
The average twelve-month price target for Translate Bio is $27.50 with a high price target of $38.00 and a low price target of $20.00. Learn more Do Wall Street analysts like Translate Bio more than its competitors? Analysts like Translate Bio stock less than the stock of other Medical companies.
What is the price targets for TBIO stock?
The high price target for TBIO is $25.00 and the low price target for TBIO is $17.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy.".
Is Tbio stock a good buy?
Translate Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.
Why is translate bio stock up?
Translate Bio stock was soaring on reports of a Sanofi takeover bid. Translate Bio stock is soaring after Sanofi agreed to acquire the company specializing in messenger RNA technology, the same used by Moderna and BioNTech in their Covid-19 vaccines.
Why is translate bio stock down?
Translate Bio stock slid steeply Thursday in response to disappointing trial data. The messenger RNA-focused biotech Translate Bio unveiled long-awaited trial data on an experimental cystic fibrosis therapy late Wednesday. And while the data showed that the treatment was generally safe, it also doesn't seem to work.
Who bought Tbio stock?
SanofiWhat happened. Shares of Translate Bio (TBIO) surged 29% on Tuesday after the U.S. biotechnology company said it agreed to be acquired by French pharmaceutical giant Sanofi (SNY -1.53%).
What happens to my translate bio stock?
As of September 14, 2021, Translate Bio common stock will cease to be traded on the NASDAQ Global Select Stock Market. Morgan Stanley & Co. International plc acted as exclusive financial advisor to Sanofi while Weil, Gotshal & Manges LLP acted as legal counsel.
What happens to translate bio?
PARIS – September 14, 2021 - Sanofi announced today the completion of its acquisition of Translate Bio, further accelerating the company's efforts to develop transformative vaccines and therapies using mRNA technology.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
TBIO POWR Grades
Quality is the dimension where TBIO ranks best; there it ranks ahead of 93.17% of US stocks.
TBIO Stock Summary
Translate Bio Inc's stock had its IPO on June 28, 2018, making it an older stock than merely 9.36% of US equities in our set.
TBIO Valuation Summary
In comparison to the median Healthcare stock, TBIO's EV/EBIT ratio is 125.94% higher, now standing at 66.2.
TBIO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Latest TBIO News From Around the Web
Below are the latest news stories about Translate Bio Inc that investors may wish to consider to help them evaluate TBIO as an investment opportunity.
Continue Researching TBIO
Want to do more research on Translate Bio Inc's stock and its price? Try the links below:
Translate Bio (NASDAQ:TBIO) Price Target and Consensus Rating
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Average Share Price and Price Target by Month
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
Translate Bio (NASDAQ:TBIO) Analyst Ratings Frequently Asked Questions
According to the issued ratings of 7 analysts in the last year, the consensus rating for Translate Bio stock is Hold based on the current 6 hold ratings and 1 buy rating for TBIO. The average twelve-month price target for Translate Bio is $29.00 with a high price target of $38.00 and a low price target of $20.00.
About Translate Bio, Inc
Transgenomic, Inc., a biotechnology company, engages in advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies, and clinical and research services primarily in the United States.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
What is Translate Bio?
Translate Bio, Inc. operates as a therapeutics company. It develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio, Inc. is based in MA, United States.
Does Zackstrade endorse or recommend investment strategies?
The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
